- Home
- CRVS vs BCYC Comparison
CRVS vs BCYC Comparison
Compare CRVS & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- BCYC
- Stock Information
- Founded
- CRVS 2014
- BCYC 2009
- Country
- CRVS United States
- BCYC United Kingdom
- Employees
- CRVS N/A
- BCYC N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- CRVS Health Care
- BCYC Health Care
- Exchange
- CRVS Nasdaq
- BCYC Nasdaq
- Market Cap
- CRVS 459.0M
- BCYC 492.1M
- IPO Year
- CRVS 2016
- BCYC 2019
- Fundamental
- Price
- CRVS $5.83
- BCYC $7.07
- Analyst Decision
- CRVS Strong Buy
- BCYC Buy
- Analyst Count
- CRVS 4
- BCYC 11
- Target Price
- CRVS $15.00
- BCYC $22.91
- AVG Volume (30 Days)
- CRVS 596.4K
- BCYC 212.9K
- Earning Date
- CRVS 11-11-2025
- BCYC 10-30-2025
- Dividend Yield
- CRVS N/A
- BCYC N/A
- EPS Growth
- CRVS N/A
- BCYC N/A
- EPS
- CRVS N/A
- BCYC N/A
- Revenue
- CRVS N/A
- BCYC $19,281,000.00
- Revenue This Year
- CRVS N/A
- BCYC N/A
- Revenue Next Year
- CRVS N/A
- BCYC $0.27
- P/E Ratio
- CRVS N/A
- BCYC N/A
- Revenue Growth
- CRVS N/A
- BCYC N/A
- 52 Week Low
- CRVS $2.54
- BCYC $6.10
- 52 Week High
- CRVS $10.00
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- CRVS 58.56
- BCYC 43.93
- Support Level
- CRVS $5.90
- BCYC $6.84
- Resistance Level
- CRVS $6.30
- BCYC $7.32
- Average True Range (ATR)
- CRVS 0.32
- BCYC 0.36
- MACD
- CRVS -0.00
- BCYC 0.02
- Stochastic Oscillator
- CRVS 53.92
- BCYC 35.83
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.